Pascaline Clerc, PhD

2018 AAAS Science & Technology Fellow; Neuroscientist; Mom; Amateur Chef; Imported From France. Tweets reflect my own opinion.

[Le Monde @lemondefr]

Inventiva réalise l’une des plus importantes levées de fonds d’une biotech en France https://t.co/IYR75X8mxR

[Pascaline Clerc, PhD @PascalineClerc]

@InventivaPharma's latest publication in @NatureComms on the effect of lanifibranor on cardiometabolic health in #MASH, co-authored by renowned cardiologists @JavedButler1 @rgiugliano @FaiezZANNAD & NATIVE co-PIs @Mayo_liverdoc & @FrancqueSven.
https://t.co/QOIYpSAAVX

[Inventiva Pharma @InventivaPharma]

Today, we announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.

Learn more: https://t.co/yBoq5GKhWq

[Pascaline Clerc, PhD @PascalineClerc]

@InventivaPharma's latest publication in @NatureComms on the effect of lanifibranor on cardiometabolic health in #MASH patients, co-authored by renowned cardiologists @JavedButler1 @FaiezZANNAD @rgiugliano & NATIVE co-PI @Mayo_liverdoc & @FrancqueSven

https://t.co/QOIYpSAAVX

[Inventiva Pharma @InventivaPharma]

Today, we announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.

Learn more: https://t.co/yBoq5GKhWq

[Inventiva Pharma @InventivaPharma]

Today, we announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.

Learn more: https://t.co/yBoq5GKhWq

[Inventiva Pharma @InventivaPharma]

#PressRelease: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D. Learn more: https://t.co/IiVZRtiGky.

Join our webcast tomorrow, 8am ET: https://t.co/A6hmlabQjn

[Inventiva Pharma @InventivaPharma]

#PressRelease: Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

To learn more, visit https://t.co/yBoq5GKhWq

[Pascaline Clerc, PhD @PascalineClerc]

Agreement with Hepalys brings lanifibranor in clinical development in Japan and South Korea.

[Inventiva Pharma @InventivaPharma]

#PressRelease: Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea.

To learn more, visit: https://t.co/f1fkXyYMyL

#NASH #MASH #lanifibranor

[FattyLiverAlliance @FattyLiverA]

@PascalineClerc from @InventivaPharma is super engaged and getting ready for tomorrow, day 1 at #EASLCongress

[Inventiva Pharma @InventivaPharma]

#PressRelease: We announce changes to the clinical development of #lanifibranor, including plans for a new Phase III trial in patients with #NASH and compensated cirrhosis.

For more information, please visit: https://t.co/OIztCbPMfH

#clinicaltrial #biotech #cirrhosis $IVA

[Pascaline Clerc, PhD @PascalineClerc]

So great to run into friend at #TLM22!! https://t.co/iRtFJCYz9C

[Pascaline Clerc, PhD @PascalineClerc]

Stop by booth #548 and say hi. #TLM22. https://t.co/FpkNIYBeuD

[Pascaline Clerc, PhD @PascalineClerc]

@NoureddinMD @AlkhouriNaim @AASLDtweets @LiverArizona @AlinaAllenMD @NoureddinNabil @schattenbergJ @ebtapper @NASH_and_coffee Congrats!

[Inventiva Pharma @InventivaPharma]

Today and tomorrow, join our CMO, Michael Cooreman, at the @CHI_Healthtech 4th Annual #NASH & #Fibrosis conference #bostondot22. Get an overview on improvement of markers of cardiometabolic health following treatment with Lanifibranor & join a discussion on Quantifying Fibrosis.

[Inventiva Pharma @InventivaPharma]

Today at 10am EST, join our CEO, Frederic Cren for a fireside chat at the @HCWCO 6th Annual #NASH #Investor Virtual Conference.

To register: https://t.co/gc8yPrw3Tq

For more information about Inventiva: https://t.co/ZyaE3Nz5IQ

#Biotech #Pharma #CEO #lanifibranor $IVA

[Pascaline Clerc, PhD @PascalineClerc]

Some news from@Inventiva with this very exciting new milestone and agreement with Sino Biopharm.

[Inventiva Pharma @InventivaPharma]

#PressRelease:@InventivaPharma and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China.

Read more about the news: https://t.co/d0psB9gGVE

#NASH #clinicaltrial #licensing #lanifibranor #china $IVA

[Alina Allen @AlinaAllenMD]

Brainstorming new terms for #NAFLD. Amazing debates and collective thinking in the room and virtually. @mcharltonmd @VladRatziu @JVLazarus @NoureddinMD @schattenbergJ @NASH_and_coffee @IanARowe @MeenaBansal2 @Mayo_liverdoc
#livertwitter #GITwitter

[Pascaline Clerc, PhD @PascalineClerc]

Thank you @EASLnews
@AASLDtweets for inviting industry representatives at the table. Critical discussion led by @FrancqueSven & Brent Tetri with peers on the impact of name/definition change on clinical trials. @InventivaPharma @MadrigalPharma @InterceptPharma @Echosens @Siemens

[FattyLiverAlliance @FattyLiverA]

Sven Francque, Stephen Dodge, PharmD, MBA, Matt Gee, Céline Fournier-Poizat, Pascaline Clerc-Brenner, Hiral Patel and Brent Tetri have an industry round table discussion today at the AASLD/EASL Nomenclature Consensus Conference discuss fatty liver disease.

[Inventiva Pharma @InventivaPharma]

#PressRelease: We announce the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with #NASH and T2D.

For more details: https://t.co/VAcPNDDAVc

#biotech $IVA #lanifibranor #liverdisease #diabetes #fibrosis

[Pascaline Clerc, PhD @PascalineClerc]

Great kick off of the #NASH nomenclature consensus meeting by @marurinella @phil_newsome7 @JVLazarus. @EASLnews @AASLDtweets

[PanNASH Initiative @PanNASH_Init]

#NAFLD-related hepatocellular carcinoma is associated with a higher proportion of patients without cirrhosis and lower surveillance rates than HCC due to other causes. Surveillance strategies should be developed @DrLoomba @DrMarkMuthiah https://t.co/JY9rgBPe7g